May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Intravitreal Injection of Anti-interleukin-2 Receptor in Experimental Autoimmune Uveoretinitis (EAU)
Author Affiliations & Notes
  • S.Q. Al-Khatib
    Laboratory of Immunology, National Eye Institute/National Institutes of Heal, Bethesda, MD, United States
  • Z. Li
    Laboratory of Immunology, National Eye Institute/National Institutes of Heal, Bethesda, MD, United States
  • P. Silver
    Laboratory of Immunology, National Eye Institute/National Institutes of Heal, Bethesda, MD, United States
  • D. Shen
    Laboratory of Immunology, National Eye Institute/National Institutes of Heal, Bethesda, MD, United States
  • H.N. Sen
    Laboratory of Immunology, National Eye Institute/National Institutes of Heal, Bethesda, MD, United States
  • R. Ursea
    Laboratory of Immunology, National Eye Institute/National Institutes of Heal, Bethesda, MD, United States
  • S.K. Srivastava
    Laboratory of Immunology, National Eye Institute/National Institutes of Heal, Bethesda, MD, United States
  • R.R. Buggage
    Laboratory of Immunology, National Eye Institute/National Institutes of Heal, Bethesda, MD, United States
  • C. Chan
    Laboratory of Immunology, National Eye Institute/National Institutes of Heal, Bethesda, MD, United States
  • R.B. Nussenblatt
    Laboratory of Immunology, National Eye Institute/National Institutes of Heal, Bethesda, MD, United States
  • Footnotes
    Commercial Relationships  S.Q. Al-Khatib, None; Z. Li, None; P. Silver, None; D. Shen, None; H.N. Sen, None; R. Ursea, None; S.K. Srivastava, None; R.R. Buggage, None; C. Chan, None; R.B. Nussenblatt, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 724. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S.Q. Al-Khatib, Z. Li, P. Silver, D. Shen, H.N. Sen, R. Ursea, S.K. Srivastava, R.R. Buggage, C. Chan, R.B. Nussenblatt; Intravitreal Injection of Anti-interleukin-2 Receptor in Experimental Autoimmune Uveoretinitis (EAU) . Invest. Ophthalmol. Vis. Sci. 2003;44(13):724.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the effect of a locally administered interleukin-2 receptor (IL-2R) blocking antibody on ocular inflammation in the afferent phase of EAU. Methods: EAU in B10.RIII mice was induced with 10 µg of human IRBP peptide 161-180 in PBS, emulsified 1:1 v/v in CFA. At day 7, animals were divided into three groups: (1) intravitreal injection of 3 µl (1.6mg/ml) of murinized rat anti-IL-2R antibody, 3c7-IgG 2a, in the right eye and 3 µl of buffered saline solution (BSS) in the left eye; (2) intravitreal injection of 3 µl of 3c7-IgG 2a in the right eye only; (3) no treatment. Fundoscopic evaluation for longitudinal follow-up of EAU was performed and scored. At day 14, all mice were killed. The eyes were harvested for histological grading. Statistics were performed with Stat View 4.5. Results: Clinically EAU developed in all three groups, although the Group (3) mice (no treatment) had significantly milder disease as compared to Groups (1) and (2). These findings were matched with histology (Table) (right eyes in group 1 and 2 vs. 3, p = 0.045). In general, the eyes receiving anti-IL-2R antibodies exhibited slightly greater inflammation as compared to the eyes without injection or injected with BSS. Interestingly, there was a relative increase in infiltrating granulocytes, particularly PMNs and a decrease of lymphocytes in the eyes treated with anti-IL-2R antibodies. Conclusions: 3c7-IgG 2a given in the late afferent phase may exacerbate ocular inflammation in a murine EAU model. Data suggest the inhibition of IL-2R might disturb the cytokine and or chemokine cascade in inflammation. The blockage of IL-2R in the afferent phase of an inflammatory process may serve as feedback signal to initiate a reflux of other inflammatory cells rather than T-lymphocytes into the target organ. Further experiments and study are needed and will provide useful information in the timing of anti-IL-2R antibody therapy for human uveitis. Clinical and Histological Scores (mean ± SEM)  

Keywords: uveitis-clinical/animal model • cytokines/chemokines • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×